Suppr超能文献

手术治疗患者中通过免疫组织化学检测的乳腺癌分子亚型表现

Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients.

作者信息

Kondov Borislav, Milenkovikj Zvonko, Kondov Goran, Petrushevska Gordana, Basheska Neli, Bogdanovska-Todorovska Magdalena, Tolevska Natasha, Ivkovski Ljube

机构信息

University Clinic for Thoracic and Vascular Surgery, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.

University Clinic for Infectious Disease and Febrile Conditions, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.

出版信息

Open Access Maced J Med Sci. 2018 Jun 6;6(6):961-967. doi: 10.3889/oamjms.2018.231. eCollection 2018 Jun 20.

Abstract

INTRODUCTION

The detection of estrogen, progesterone and HER-2 neu receptors on the surface of the tumour cell is a significant prognostic factor, alone or in combination. The presence or absence of receptors on the surface of the tumour cell is associated with the conditional gene expression in the tumour cell itself. Based on these genetically determined expressions of the tumour cell, five molecular subtypes of breast cancer have been classified on the St. Gallen International Expert Consensus in 2011 that can be immunohistochemically detected, with each subtype manifesting certain prognosis and aggression.

AIM

Analyzing the presentation of molecular subtypes of breast cancer that are immunohistochemically detected in surgically treated patients at the Clinic for Thoracic and Vascular Surgery.

MATERIAL AND METHODS

We used the international classification on molecular subtypes of breast cancer which divides them into: Luminal A (ER+ and/or PR+, HER-2 negative, Ki-67 < 14%), Luminal B with HER-2 negative (ER+ and/or PR+, HER-2 negative, Ki-67 ≥ 14%), Luminal B with HER-2 positive (ER+ and/or PR+, HER-2+, any Ki-67), HER-2 enriched (ER-, PR-, HER-2+), and basal-like (triple negative) (ER-, PR-, HER-2 negative, CK5/6+ and/or EGFR+). A total of 290 patients, surgically treated for breast cancer, were analysed during 2014.

RESULTS

In our analysis, we found that Luminal A was present in 77 (26.55%) patients, Luminal B HER-2 negative was present in 91 (31.38%) patients, Luminal B HER-2 positive was present in 70 (24.14%) patients, HER-2 enriched was present in 25 (8.62%) patients and basal-like (or triple negative) was present in 27 (9.31%) patients.

CONCLUSION

Detecting the subtype of breast cancer is important for evaluating the prognosis of the disease, but also for determining and providing an adequate therapy. Therefore, determining the subtype of breast cancer is necessary for the routine histopathological assay.

摘要

引言

检测肿瘤细胞表面的雌激素、孕激素和HER-2 neu受体是一个重要的预后因素,单独或联合检测均如此。肿瘤细胞表面受体的存在与否与肿瘤细胞自身的条件性基因表达相关。基于肿瘤细胞的这些基因决定的表达情况,2011年圣加仑国际专家共识对乳腺癌的五种分子亚型进行了分类,这些亚型可通过免疫组织化学检测,每种亚型都有特定的预后和侵袭性表现。

目的

分析在胸心血管外科接受手术治疗的患者中通过免疫组织化学检测出的乳腺癌分子亚型的表现情况。

材料与方法

我们采用了乳腺癌分子亚型的国际分类方法,将其分为:腔面A型(雌激素受体[ER]+和/或孕激素受体[PR]+,HER-2阴性,Ki-67<14%),HER-2阴性的腔面B型(ER+和/或PR+,HER-2阴性,Ki-67≥14%),HER-2阳性的腔面B型(ER+和/或PR+,HER-2+,任意Ki-67),HER-2富集型(ER-,PR-,HER-2+),以及基底样型(三阴性)(ER-,PR-,HER-2阴性,细胞角蛋白5/6[CK5/6]+和/或表皮生长因子受体[EGFR]+)。2014年期间,我们共分析了290例接受乳腺癌手术治疗的患者。

结果

在我们的分析中,我们发现77例(26.55%)患者为腔面A型,91例(31.38%)患者为HER-2阴性的腔面B型,70例(24.14%)患者为HER-2阳性的腔面B型,25例(8.62%)患者为HER-2富集型,27例(9.31%)患者为基底样型(或三阴性)。

结论

检测乳腺癌亚型对于评估疾病预后很重要,同时对于确定并提供适当的治疗也很重要。因此,确定乳腺癌亚型对于常规组织病理学检测是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b73f/6026408/6d836ea6a761/OAMJMS-6-961-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验